Laventair Ellipta-H-C-PSR-S-0048: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Advanced pharmaceutical formulation for targeted therapeutic intervention.
Source
European Medicines Agency
Additional Information
medication.label.product_type
scientific-conclusion
medication.label.permit_number
EMA/565819/2024
medication.label.permit_validity
First published: 2024-12-12T14:54:05Z
Documents
Related Medications
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
AI Voice
Listen to the article content live